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Abstract In vitro binding of (3-[lZSllTyr)-endothelin-1 ([12SllET- 
1) and (3-[~ZSlITyr)-hig ET-1(1-38) ([~ZSlIhig ET-1) to plasma 
proteins of healthy humans, cardiac patients and normotensive 
and hypertensive rats was investigated by equilibrium dialysis. 
Binding of both tracers was similar in plasma from healthy hu- 
mans, patients with congestive heart failure, and following myo- 
cardial infarction (-60%), and marginally higher in rat plasmas 
(~70%). Binding of [~ZSlIET-1 to human plasma could be 
explained by binding to human serum albumin. Endogenous 
plasma ET-1 levels were ~9 pg/ml in healthy humans, and ~ 12-16 
pg/ml in cardiac patients; big ET-1 concentrations were approx- 
imately two- to threefold higher. ET-1 bound to plasma protein 
was partly lost in column extraction. In rat isolated perfnsed 
hearts, the coronary dilator and constrictor potency of exogenous 
free and albumin-bound ET-1 was similar, whereas the kinetics 
of endogenous ET-1 was impeded by tight binding to ET recep- 
tors. The data indicate that binding of ET-I to plasma proteins 
is without effect on peptide vasoactivity, but binding to tissue 
receptors greatly impedes its tissue kinetics. 
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1. Introduction 
The endothelins (ET-1, ET-2 and ET-3) are a family of pol- 
ypeptides with potent local actions [1,2]. ET-1 stimulates the 
release of several vasoactive hormones, including atrial natriu- 
retic peptide, aldosterone and catecholamines [3]. The ET-1 
concentration in the peripheral circulation is in the order of 
several pg/ml, but elevated levels have been observed in a num- 
ber of different disease states, including congestive heart failure 
[4,5], myocardial infarction [6], and hypertension [7]. However, 
neither the causes nor the significance of elevated plasma ET- 1 
concentrations are clear. The increases may reflect pathophys- 
iological changes or simply mark the progression of endothelial 
cell damage. 
Because the extent of drug binding to plasma protein influ- 
ences the interpretation of total drug concentrations [8], we 
hypothesized that the knowledge of plasma protein binding of 
ET-1 and big ET-1 in healthy subjects and cardiac patients may 
be of interest in the interpretation of the plasma levels of these 
peptides. Therefore, the aim of the present study was (i) to 
*Corresponding author. Fax: (43) (316) 323-5414. 
investigate the binding of ET-1 and big ET-1 to plasma of 
healthy humans, patients with heart failure or myocardial in- 
farction, and of normotensive and hypertensive rats and (ii) to 
determine the effect of plasma binding of ET-1 on its vasoactiv- 
ity. An additional aspect included possible effects of protein 
binding on the determination of ET-1 in native plasma. 
2. Materials and methods 
2.1. Materials 
(3-[125I]Tyr)-endothelin-1 and(3-[125I]Tyr)-big ET-l(1-38) were pur- 
chased from Anawa Trading (Wangen, Switzerland). Bovine serum 
albumin (99% purity) and human serum albumin (from fraction V, 
essentially fatty acid free) were from Sigma Chemie (Vienna, Austria). 
SB 209670 ((1RS,2RS,3RS)-3-(2-carboxymethoxy-4 -methoxyphenyl)- 
1-(3,4-methylenedioxyphenyl)-5(prop-l-yloxy)indane-2-carboxylic 
acid)) was a gift from the Dagenham Research Centre (Dagenham, 
England). Extraction was performed on silica-C2 Ethyl Cartridges 
(Spe-ed, 500 mg, Inovex, Vienna, Austria). Blood (5-7 ml) from healthy 
human volunteers (mean age 26.3 + 1.2 years) and cardiac patients 
suffering from congestive heart failure (mean age 59.5 + 2.5 years; 
primary causes: idiopathic and ethylic ardiomyopathy) or myocardial 
infarction (mean age 79.3 + 4.6 years; maximal delay between insult 
and blood collection: ~7 h) was collected in K+-EDTA-tubes, immedi- 
ately centrifuged, the plasma separated and stored at -70°C pending 
analyses. Plasma from normotensive Sprague Dawley (S-D) and Wis- 
tar-derived (WAG) rats (both normotensive) and genetically hyperten- 
sive (GH) rats [9] was obtained from the thoracic cavity following 
removal of the heart for another purpose. All rats were bred locally. 
2.2. Equilibrium dialysis 
All experiments were performed with an equilibrium dialysis system 
(Dianorm) at 37°C using teflon cells of 0.2 ml half cell volume as 
previously described [10]. Equilibrium time was 7 h (ET-1) and 17 h (big 
ET-1), respectively. The buffer cell was filled with 0.2 ml [~zSI]ET-1 or 
[~ 25I]big ET- 1 as tracer (10,000-12,000 cpm) dissolved in dialysis buffer 
of the following composition (mM): NaH2PO4×I H:O 15, 
Na2HPOaX2 H20 85, NaC1 50, Triton X-100 0.1%; pH 7.4). The 
second half cell was filled with the respective protein solution (plasma, 
bovine or human serum albumin). Following freezing and thawing, the 
pH of rat plasmas varied between 6.0 and 8.1 which was without effect 
on protein binding. Non-specific binding to the dialysis membrane 
(Thomapor, Reichelt Chemietechnik, Heidelberg, Germany); mol. 
weight cutoff: ~ 15,000 Da) amounted to 6% and was neglected in the 
calculations. The radioactivity inboth cells was determined by counting 
100/zl of each cell in a Gamma-counter (Packard Canberra, Vienna). 
Binding percentages were calculated according to the formula: % 
bound = [(B-A)/B] x 100 with B being the molar concentration of the 
tracer in the protein compartment, and A in the protein-free compart- 
ment [10]. When filled with plasma, the volume of cell B increased up 
to 20% (ET-1) and 30% (big ET-1) due to osmosis which was taken into 
account in the calculations. 
2.3. Determination of ET-1, big ET-1, and serum albumin in plasma 
Thawed plasma was centrifuged, iluted 1:10 with RIA buffer and 
passed over C2-columns activated with ethanol (2 ml) and water (5 ml). 
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After washing ET-1 was eluted with 70% acetonitrile (2 ml), the eluate 
freeze-dried, and the residue taken up in 400 pl RIA buffer. Im- 
munoreactive ET-1 and big ET-1 were determined by specific RIAs as 
previously described [11,12]. The serum albumin content of human 
plasmas was determined in a local clinical laboratory using conven- 
tional techniques. 
2.4. Functional experiments 
The effect of plasma protein binding on ET-l-induced vasodilation 
and vasoconstriction was studied in rat isolated hearts perfused at 
constant flow as described previously [13]. Concentration response 
curves of ET-1 (1-300 pg/ml) were established in the absence and 
presence of bovine serum albumin (40 g/l) using separate hearts. ET-1 
solutions were incubated with bovine serum albumin for 10 min at 37°C 
prior to infusion into the heart. 
2.5. Effect of  ET-1 tissue binding on ET-1 release 
The effect of binding of ET-1 to tissue ET receptors on ET-1 tissue 
kinetics was assessed by blocking ET receptors with the non-selective 
ET receptor antagonist, SB 209670 [14]. The blocker was infused with 
the perfusion buffer, and release of endogenous ET-1 into the coronary 
circulation and the interstitial f uid measured as described previously 
[13]. 
2.6. Stat&tics 
All binding experiments were carried out in quadruplicate he deter- 
minations of ET-1 and big ET-1 plasma levels in triplicate, and the 
determinations of plasma albumin in duplicate. In all cases, the mean 
was determined and counted as 1 determination ( ). Statistical differ- 
ences were analyzed by unpaired two-tailed Student's t test. A P-value 
< 0.05 was considered significant. 
3. Results 
ET-1 binding data, ET-1 plasma concentrations, and albu- 
min plasma concentrations for humans and rats are summa- 
rized in Table 1. Following addition of [125I]ET-1 (final concen- 
tration ~5 pM) to human or rat plasma, ~60% were bound in 
human plasma, and ~ 70% in rat plasma. There was no difference 
between healthy human males and females, nor between pa- 
tients and controls. The binding of ET-1 to rat plasma was 
independent of rat strain and blood pressure. Compared to 
healthy controls, plasma ET-1 levels were 1.7 times higher in 
patients with heart failure and 1.3 times higher in patients with 
myocardial infarction (P < 0.05). In rats, plasma levels were 
Table 1 
Plasma binding of [a25I]ET-1, plasma ET-1 concentration and plasma 
albumin concentration i  humans and rats 
[125I]ET-1 bound plasma ET-1 Plasma albumin n 
(% of total) (pg/ml) (g/dl) 
Human 
male 58.5 + 1.3 9.2 + 0.2 5.2 + 0.1 5 
female 58.0 + 1.5 8.8 + 0.2 4.9 + 0.1 5 
CHF 55.6 + 0.8 15.7 + 1.8" 4.1 + 0.1" 14 
MI 62.0 + 2.4 12.1 + 0.7* 4.1 + 0.2* 7 
Rats 
S-D 69.4 + 0.9 9.0 + 0.1 2.9 + 0.1 11 
WAG 70.6 + 0.9 9.4 + 0.1 n.d. 5 
GH 71.7 + 1.2 9.2 + 0.1 n.d. 5 
Binding to plasmas was determined by spiking with [125I]ET-1 (~ 10,000 
cpm) and levels of plasma ET-1 were determined by RIA as described 
in section 2. Probands were either healthy (males, females) or suffered 
from congestive heart failure (CHF) or myocardial infarction (MI). 
Rats were either normotensive (Sprague-Dawley, S-D; Wistar-derived, 
WAG) or genetically hypertensive (GH). n.d., not determined. Data are 
means + S.E.M. of n plasmas assayed in each group. *P < 0.05 vs 
healthy controls (males). 
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Fig. l. Concentration-dependence of ET-I binding to human serum 
albumin. Solutions of purified albumin (2-50 mg/ml) were dialyzed 
against phosphate buffer spiked with [125I]ET-1. Data are mean val- 
ues + S.E.M. of 3 determinations in quadruplicate. 
similar in all groups studied. Plasma albumin concentrations 
were 20% lower in both patient groups than healthy individuals 
(P < 0.05) and the albumin content of rat plasma was even 
lower, as reported previously [15]. When [125I]ET-1 was dialyzed 
against human serum albumin (2-50 g/l), binding increased 
from 11.2 _+ 5.9 to 68.0 + 2.5% of total (Fig. 1). 
Binding of [125I]big ET-1 (~5 pM) to human and rat plasma 
and big ET-1 plasma concentrations are shown in Table 2. 
Again, binding percentages were similar for all groups. Binding 
of [125I]big ET-1 to plasma from WAG and GH rats was slightly 
higher than binding to plasma from S-D rats (P < 0.05). Big 
ET-1 plasma concentrations were similar in healthy human 
males and females (mean: 24.9 _+ 0.7 pg/ml), and increased 1.8- 
fold in heart failure and 1.4-fold in infarct patients (P < 0.05). 
Big ET-1 levels in rats were clearly dependent on rat strain and 
blood pressure: in both normotensive WAG and hypertensive 
rats, big ET-1 levels were only one half of those in S-D rats 
(P < 0.05; Table 2). 
The effect of plasma protein binding on ET-1 extraction 
during plasma work-up is summarized in Table 3. Human 
plasma spiked with [~25I]ET-1 was dialyzed as above, and the 
contents of dialyis cells A (non-bound fraction) and B (plasma 
protein-bound plus free fraction) were chromatographed sepa- 
rately. In agreement with our previous determinations [13], 
-90% of radioactive peptide loaded onto columns was re- 
covered. However, whereas unbound (free) label was in toto 
contained in the elution phase, with no radioactivity appearing 
in the wash phase prior to elution, part of[~25I]ET-1 (~ 15%) was 
lost with the wash phase, when post-dialysis plasma containing 
albumin-bound ET-1 was chromatographed. Therefore, to de- 
termine the recovery of plasma-borne ET-1 in column chroma- 
tography correctly, radioactive tracer must be added to a 
plasma sample and not to buffer as done frequently. 
To determine the effect of plasma protein binding of ET-1 
on its vasodilator and vasoconstrictor potency, ET-1 was in- 
fused into rat hearts in the absence and presence of albumin. 
In the absence of albumin, ET-1 concentrations between ~ 1 and 
~20 pg/ml were vasodilatory, whereas higher concentrations 
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Fig. 2. Effect of bovine serum albumin (BSA) on vasodilator and 
vasoconstrictor effects of ET-1 in isolated perfused hearts. Initial coro- 
nary perfusion pressure was raised to 100 mmHg by perfusing at a 
higher than normal rate. BSA was added to ET-1 solution 10 min prior 
to experiment. Data are mean values + S.E.M. of 3 determinations 
each. 
constricted the coronary vessels resulting in an increase in cor- 
onary perfusion pressure up to ~ 160 mmHg (Fig. 2). However, 
following incubation of the peptide with serum albumin, pre- 
sumably resulting in binding of ET-1 to the protein, the vasodi- 
latory component was unaffected, but the vasoconstrictor com- 
ponent was blunted, resulting in a slight increase in the ECs0 
value. Serum albumin alone (vehicle) had no effect on either 
component (data not shown). 
Finally, the effect of tissue binding of ET-1 on ET-1 release 
from isolated perfused hearts was investigated (Fig. 3). Under 
control conditions, only small amounts of ET-1 were released 
into the coronary effluent over 255 min of perfusion. However, 
when the mixed ETA-ET B receptor antagonist SB 209670 (5 
/,tM) was infused with the perfusion buffer, presumably result- 
ing in time-dependent blockade of endothelial nd myocardial 
ET receptors, ET-1 release was steadily augmented between 
2.3-fold (30 min of perfusion with antagonist) and 8-fold (3.5 
h of perfusion with antagonist). Over the same time course, 
ET-1 secretion into interstitial fluid was always much lower 
than that into coronary effluent and increased only 2-3-fold 
(data not shown). 
4. Discussion 
The main goal of this study was to assess the effects of ET-1 
plasma binding on its vasodilator and vasoconstrictor activity 
and to obtain information on the effect of plasma binding of 
ET-1 on the determination f ET-1 plasma concentration. An- 
other aim was to determine whether plasma protein binding of 
ET-1 and big ET-1 was different in cardiac patients and hy- 
pertensive rats compared to controls and whether such differ- 
ences may explain increased peptide levels found in these con- 
ditions. 
Following standard techniques [16], in vitro binding of ET-1 
and big ET-1 in human plasma of healthy control subjects and 
cardiac patients was of only moderate xtent, which indicates 
that no major effects on plasma-derived kinetic parameters, e.g. 
plasma clearance of exogenous or endogenous peptide are to 
be expected [17]. In rat plasma, binding of both ET-1 and big 
ET-I was higher than in human plasma, a species difference 
observed previously with a variety of drugs and endogenous 
substances. In human, and presumably also rat plasma, binding 
to the albumin molecule probably accounted for most binding 
in plasma. Serum albumin is involved in the binding and trans- 
port of many endogenous and exogenous substances and is an 
important factor in the pharmacokinetics of a variety of drugs 
[18]. The higher binding percentage of ET-1 to rat plasma at 
a significantly lower plasma albumin concentration compared 
to human plasma (Table 1) may indicate that one or more other 
binding proteins of lesser importance are involved, or that the 
binding affinity to rat albumin is higher. This also applies for 
the ET-I binding data obtained with the plasmas of cardiac 
patients (Table 1) and the big ET-1 binding data obtained with 
plasmas from congestive heart failure patients (Table 2). The 
nature of the binding interaction was not studied, but is pre- 
sumably similar to the interaction of serum albumin with other 
polypeptide hormones. 
The present study has confirmed previous reports which 
showed that plasma ET-1 and big ET-1 levels are increased in 
humans with failing hearts or following myocardial infarction. 
Due to the lack of comparable analytical procedures among 
laboratories and definition of a range of normal values, the 
significance of increased ET-1 and big ET-1 levels in these 
disease states is obscure. The present results how that plasma 
protein binding of both peptides is not increased in cardiac 
patients compared to controls and, therefore, the higher total 
plasma concentrations in the patients cannot be explained with 
a lower free fraction (total concentration equals free concentra- 
tion/free fraction) [8]. Rather, the higher total peptide concen- 
trations are a true reflection of increased synthesis and/or de- 
creased removal in cardiac patients. 
Of importance is the observation that binding of ET-1 to 
albumin had no effect on its potency as a vasodilator. Clearly, 
albumin-bound ET-1 is capable of activating ET receptors, 
probably because the binding affinity to the albumin molecule 
is much lower (presumably in the micromolar range) than the 
affinity to ET receptors (nanomolar range or lower) [19]. An 
insufficient time of contact (10 min) between the low (vasodila- 
tory) concentrations of ET-1 and albumin which would lead to 
incomplete binding to the protein is unlikely to account for this, 
Table 2 
Plasma binding of big [~2SI]ET-1 and plasma big ET-1 concentration i
humans and rats 
[125I]big ET-1 bound plasma big ET-1 n 
(% of total) (pg/ml) 
Human 
male 65.0 + 1.1 23.7 + 0.8 5 
female n.d. 26.1 + 0.7 5 
CHF 58.4 + 2.2 44.0 _+ 7.2* 5 
MI 59.1 + 1.4" 33.8 + 4.6* 6 
Rats 
S-D 71.1 + 0.9 45.9 + 9.0 11 
WAG 76.2 + 1.1" 19.4 + 0.5* 5 
GH 77.6 + 0.9* 21.3 + 0.9* 5 
Binding to plasma was determined by spiking with big [125I]ET-1 
(~ 10,000 cpm). For other details, see legend to Table 1. *P < 0.05 
vs healthy controls (males) and S-D rats, respectively. 
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because the binding reaction is generally complete after several 
seconds. The reasons for the slight, albeit significant non-paral- 
lel displacement of the vasoconstrictor portion of the ET-1 
concentration response curve are not clear. 
Of great significance is our observation that the rate of ap- 
parence of ET-1 in the coronary effluent was considerably 
increased following infusion of SB 209670, a non-peptide ET 
receptor antagonist, compared to control rates in the absence 
of blocker. One of us has previously shown that the coronary 
endothelium of isolated perfused rat hearts releases ET- 1 both 
into the coronary effluent and the cardiac interstitial f uid, but 
the rate of release into the coronary lumen was much higher 
than that towards the interstitium [13]. The present data show 
that ET-I is probably actually released preferentially to the 
abluminal side of endothelial cells, followed by tight binding to 
and time-dependent saturation of ET receptors of cardiomy- 
ocytes and/or endothelial cells. In the presence of the antagonist 
SB 209670, however, the binding capacity of tissue receptors 
was greatly reduced, resulting in diffusion of the peptide back 
into the coronary lumen. Because occupation of the receptors 
by antagonist is time-dependent, the rate of appearance of ET- 1 
in the coronary lumen increased steadily (Fig. 3). Thus, our 
previous observations of increased plasma levels of endogenous 
ET-1 in rats following administration of the antagonist Ro 
46-2005 [20] or bosentan [21] are most likely due to displace- 
ment of ET-1 from tissue receptors. The present data also 
support he model of stoichiometric binding of ET-1 to recep- 
tors according to which most of tissue ET-1 is bound to recep- 
tors with consequent low levels of free peptide both in tissues 
and plasma [22]. 
Finally, the present study shows that binding of ET-1 to 
serum albumin also affects the determination f ET-1 in human 
plasma. We found that -15% of ET-1 added to the plasma 
compartment was contained in the breakthrough phase and the 
following wash phase, whereas for the dialysis buffer compart- 
ment which contained only unbound peptide, no ET-1 was 
measured in these phases. Therefore, plasma protein binding 
impedes adsorption of ET-1 onto the column prior to elution, 
resulting in reduced recovery. In part, this may also be reflected 
in the lower plasma big ET-1 concentrations in Wistar-derived 
and genetically hypertensive rats compared to Sprague-Dawley 
rats (Table 2) due to higher binding in the former two groups. 
The loss is probably still greater when using more hydrophobic 
Table 3 
Effect of plasma protein binding on column chromatography of ET-1 
Dialysis cell A Dialysis cell B 
cpm % cpm % 
cpm added 8076 + 201 100 20657 + 329 100 
onto column 
Recovery in 36 + 36 0.4 _+ 0.4 3120 + 475 15.1 + 2.3 
wash phase 
Recovery in 7268 + 258 90.0 + 2.9 15586 +844 75.4 + 3.7 
eluate 
Total recovery 7303 + 259 90.4 + 3.1 18723 +787 90.6 + 3.3 
Plasma of healthy probands was spiked individually with - 10,000 cpm 
[]25I]ET-1 and dialyzed in quadruplicate. Part of the contents (100 ,ul) 
of dialysis cell A (buffer containing unbound peptide) and B (plasma 
containing unbound and bound peptide) of each replicate (total vol- 
ume: 400 pl) were added separately onto preconditioned C2-columns, 
followed by washing of columns and elution of peptide. Data are 
means + S.E.M. of 8 plasmas assayed. 
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Fig. 3. Effect of blockade of ET receptors on secretion of endogenous 
ET-1 into coronary effluents of isolated perfused hearts. Following 
establishement of baseline conditions (45 min), hearts were perfused 
with vehicle or SB 209670 and ET-1 secretion rate determined by RIA. 
Mean values + S.E.M. of 3 determinations each. 
columns (C 18) for which extraction efficiency is frequently only 
60-70% for free peptide [23]. Therefore, standardized extrac- 
tion and assay procedures need to be established for a meaning- 
ful interpretation of ET-1 and big ET-1 plasma levels. 
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